TITLE

CHMP ADOPTS POSITIVE OPINION FOR ALEXION'S SOLIRIS IN EUROPE

PUB. DATE
June 2007
SOURCE
Worldwide Biotech;Jun2007, Vol. 19 Issue 6, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that the Committee for Human Medicinal Products of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Soliris, a drug from Alexion Pharmaceuticals Inc. The drug is for patients with paroxysmal nocturnal hemoglobinuria (PNH). Soliris is intended to reduce hemolysis in patients with PNH. The committee evaluated Soliris under the European Accelerated Assessment procedure.
ACCESSION #
25121451

 

Related Articles

  • New biologic: Soliris.  // Formulary;Apr2007, Vol. 42 Issue 4, p215 

    The article reports on the approval of recombinant monoclonal antibody eculizumab from Alexion Pharmaceuticals Inc. for the treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis. Its efficacy is evaluated in a randomized placebo-controlled 26-week study, and a single-arm 52-week...

  • Alexion Pharmaceuticals. Investor's Business Daily // Investors Business Daily;4/13/2015, pA02 

    The article focuses on the approval given to Alexion Pharmaceuticals Inc. (ALXN) which will allow update of the label of its drug Soliris for paroxysmal nocturnal hemoglobinuria to include patients without history of transfusion.

  • Alexion, Others Show Resilience After Breakouts. KEN SHREVE // Investors Business Daily;12/3/2014, pB08 

    Stocks that show resilience and trade tightly after a are worth watching. Why? Because price action like this can often a new entry after an initial breakout.

  • EARNINGS ROUNDUP.  // BioWorld Today;10/27/2008, Vol. 19 Issue 209, p3 

    The article reports that Alexion Pharmaceuticals Inc. of Cheshire, Connecticut reported total revenue of $76.5 million for the third quarter of 2008. According to the article, this came from sales of paroxysmal nocturnal hemoglobinuria drug Soliris which were up from the $21.8 milion in revenues...

  • American Society of Hematology 2007.  // BioWorld Today;12/11/2007, Vol. 18 Issue 239, p3 

    The article reports on the open-label clinical study conducted by Alexion Pharmaceuticals Inc. According to the Cheshire, Connecticut-based company, paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder, was more likely for the general public to have than chronic kidney disease....

  • OTHER NEWS TO NOTE.  // BioWorld Today;1/30/2009, Vol. 20 Issue 19, p2 

    This section offers news briefs on the biopharmaceutical industry. The European Union (EU) has approved the use of Zavesca from Actelion Ltd. in treating progressive neurological manifestations of Niemann-Picktype C disease. Alexion Pharmaceuticals Inc. has announced that Health Canada approved...

  • LONG-TERM SOLIRIS TREATMENT IMPROVES KIDNEY FUNCTION.  // Biotech Business;Jan2010, Vol. 23 Issue 1, p1 

    The article reports on the findings of Alexion Pharmaceuticals, Inc. from its 26-week extension of the AEGIS study, an open-label registration study focused on showing Soliris as treatment for Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). It affirmed that patients with...

  • Alexion Soars On Earnings Report.  // BioWorld Today;7/26/2007, Vol. 18 Issue 144, p3 

    The article reveals the increase in the shares of Cheshire, Connecticut-based Alexion Pharmaceuticals Inc. after it released its second-quarter earnings, which showed a smaller than predicted loss. Alexion reported total revenues of $9.8 million, all from sales of recently launched Soliris, and...

  • Alexion Defies Biotech's Slow Sales Trend; Beats Estimates. Boggs, Jennifer // BioWorld Today;7/22/2011, Vol. 22 Issue 141, p1 

    The article reports on the second quarter earnings of Alexion Pharmaceuticals Inc. in 2011, which prompted the company to increase the sales guidance for its paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris. The price of the stocks of the company rose 9 percent on July 21, 2011 to close at...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics